bpc-157 peptide clinical trials – Research Frontiers | Stable Gastric Pentadecapeptide
Description
The Croatian pharmaceutical company Pliva advanced BPC-157 into a Phase 2 clinical trial for inflammatory bowel disease under the designation PL 14736, which was completed but was never published in full
The NIH Office of Dietary Supplements has established no Tolerable Upper Intake Level (UL), meaning these high label doses do not pose the safety risks their large numbers might suggest
A tracking code will be sent out once your payment has been fully received
Our peptides are backed by verified COA, ensuring researchers can trust in their efficacy and safety
